TP53 and non-small cell lung carcinoma: For example, HSPs pharmaceutical inhibitors targeting mutant p53-HSP complexes that lead to accumulation of mutant p53 by inactivating the p53 ubiquitination by MDM2, are investigated in clinical trials of non-small cell lung cancer (NSCLC) [31].